NASDAQ:RNAZ TransCode Therapeutics (RNAZ) Stock Price, News & Analysis $2.01 -0.05 (-2.43%) Closing price 04:00 PM EasternExtended Trading$1.99 -0.02 (-0.80%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsSEC Filings About TransCode Therapeutics Stock (NASDAQ:RNAZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TransCode Therapeutics alerts:Sign Up Key Stats Today's Range$2.01▼$2.1250-Day Range$2.06▼$9.6052-Week Range$1.83▼$20.99Volume22,319 shsAverage Volume126,342 shsMarket Capitalization$34.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts. Read More TransCode Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreRNAZ MarketRank™: TransCode Therapeutics scored higher than 3% of companies evaluated by MarketBeat, and ranked 892nd out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingTransCode Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageTransCode Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about TransCode Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of TransCode Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransCode Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about TransCode Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.18% of the float of TransCode Therapeutics has been sold short.Short Interest Ratio / Days to CoverTransCode Therapeutics has a short interest ratio ("days to cover") of 1.51, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TransCode Therapeutics has recently increased by 9.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTransCode Therapeutics does not currently pay a dividend.Dividend GrowthTransCode Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for TransCode Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for RNAZ on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TransCode Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.10% of the stock of TransCode Therapeutics is held by insiders.Percentage Held by InstitutionsTransCode Therapeutics has minimal institutional ownership at this time.Read more about TransCode Therapeutics' insider trading history. Receive RNAZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNAZ Stock News HeadlinesTransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone MetastasisAugust 31 at 8:05 AM | prnewswire.comVirax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TVAugust 7, 2026 | finance.yahoo.comA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names distributes income every single Thursday, with payouts reported as high as $1,051 a month. Chief Income Strategist Tim Plaehn breaks down the fund's real Thursday distribution history, how the income is generated, and how to buy it in any brokerage account.September 2 at 1:00 AM | Investors Alley (Ad)TransCode Therapeutics, Inc.July 22, 2026 | edition.cnn.comTransCode Therapeutics Inc RNAZJuly 3, 2026 | morningstar.comMTransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks TranscriptJune 18, 2026 | seekingalpha.comRNAZ: Introducing RNA therapeuticsJune 8, 2026 | msn.comTransCode Therapeutics to Host R&D Webcast on June 18, 2026June 8, 2026 | prnewswire.comSee More Headlines RNAZ Stock Analysis - Frequently Asked Questions How have RNAZ shares performed this year? TransCode Therapeutics' stock was trading at $6.83 at the beginning of the year. Since then, RNAZ stock has decreased by 70.6% and is now trading at $2.01. How were TransCode Therapeutics' earnings last quarter? TransCode Therapeutics Inc. (NASDAQ:RNAZ) released its quarterly earnings data on Friday, August, 14th. The company reported ($7.17) earnings per share for the quarter. When did TransCode Therapeutics' stock split? Shares of TransCode Therapeutics reverse split on the morning of Tuesday, January 16th 2024.The 1-40 reverse split was announced on Tuesday, January 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did TransCode Therapeutics IPO? TransCode Therapeutics (RNAZ) raised $25 million in an initial public offering (IPO) on Friday, July 9th 2021. The company issued 6,250,000 shares at $4.00 per share. How do I buy shares of TransCode Therapeutics? Shares of RNAZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TransCode Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that TransCode Therapeutics investors own include Plug Power (PLUG), AMC Entertainment (AMC), Nuwellis (NUWE), ARMOUR Residential REIT (ARR), BIOLASE (BIOL) and Imperial Petroleum (IMPP). Company Calendar Last Earnings8/14/2026Today9/02/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 3 weeks, RNAZ's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RNAZ CIK1829635 Webwww.transcodetherapeutics.com Phone857-837-3099FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)($52.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-875.35% Return on Assets-37.46% Debt Debt-to-Equity RatioN/A Current Ratio1.97 Quick Ratio1.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.64) per share Price / Book-1.23Miscellaneous Outstanding Shares16,930,000Free Float16,914,000Market Cap$34.03 million OptionableNot Optionable Beta1.17 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:RNAZ) was last updated on 9/2/2026 by MarketBeat.com Staff. From Our PartnersPass by August 7… or wait until 2027?Right now, crypto investors are watching Washington closely. With lawmakers returning from the August recess, ...Crypto 101 Media | SponsoredGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredWhy Boston Ships In Natural Gas It Already Has at HomeA tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natu...Porter & Company | SponsoredThese 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAIElon Musk calls it the most disruptive force in history. Sam Altman is reportedly preparing a new venture afte...Stansberry Research | Sponsored200 companies were warned. 40% found the intruder.A cybersecurity firm warned roughly 200 companies they might have a fake employee on payroll. After investigat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
